Group items tagged

Novartis has announced results from the Monaleesa-3 trial at the European Society for Medical Oncology (ESMO) Congress 2019.

ImmunoGen has presented full data from Phase 3 Forward I study of Mirvetuximab Soravtansine in ovarian cancer at the ESMO 2019 Congress in Barcelona, Spain.

At ESMO 2019 Congress, Merck unveiled interim results from pivotal neoadjuvant/adjuvant phase 3 Keynote-522 trial during Presidential Symposium.

Biosimilars in oncology: Less than 50% of oncologists were prescribing biosimilars, primarily due to concerns regarding immunogenicity and extrapolation.

Pfizer has reported positive data from the interim analysis of the Phase III BEACON CRC clinical study being conducted to assess Braftovi.

Final data from BMS's Phase III CheckMate-227, Part 1 study was presented at the European Society of Medical Oncology conference in September.

Patients with advanced non-small cell lung cancer may have tumour biopsy replaced with a simple blood test to assess their treatment options.

Final results from the Phase III FLAURA trial investigating AstraZeneca's Tagrissofinal reinforce the therapy as the SOC for first-line treatment of patients with EGFRm advanced NSCLC.

Biopharmaceutical company BeiGene has presented data on its two investigational drug candidates, anti-PD-1 antibody tislelizumab and PARP inhibitor pamiparib.

Roche's Tecentriq: Results demonstrated that first-line treatment of patients with advanced non-small cell lung cancer and high programmed cell death ligand-1 expression who used Roche's Tecentriq monotherapy resulted in improved overall survival compared with platinum-based chemotherapies.